A securities class action lawsuit has been initiated against Inovio Pharmaceuticals Inc. (NASDAQ: INO), alleging the company made materially false and misleading statements regarding its CELLECTRA device and regulatory pipeline. The complaint centers on assertions that defendants misrepresented manufacturing capabilities of the CELLECTRA platform, overstated the regulatory prospects for the company's INO-3107 candidate, and failed to disclose material impediments to submitting a Biologics License Application to the FDA within previously communicated timeframes.
Investors who acquired Inovio securities during the period spanning October 10, 2023 through December 26, 2025 may qualify as class members in the litigation. The case presents potential compensation opportunities for affected shareholders, contingent upon the outcome of the proceedings and subsequent settlement or judgment terms.
A critical deadline for lead plaintiff motions has been established for April 7, 2026. Legal counsel specializing in securities litigation emphasizes the importance of timely action for eligible investors, as participation deadlines and claim requirements are subject to strict procedural rules. Investors who believe they have suffered losses are advised to consult with qualified securities attorneys to understand their rights and obligations under the class action framework.